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Introduction
Cefuroxime axetil (CA) (Fig. 1) is an orally administered, 
semi-synthetic acetoxyethyl ester of cefuroxime and it 
belongs to the second generation of cephalosporins. CA is 
rapidly hydrolyzed by nonspecific esterase in the intestinal 
mucosa and blood to the active form, cefuroxime. The drug 
represents high antibacterial activity against wide range of 
Gram-positive and Gram-negative microorganisms. CA is 
mainly used in the treatment of respiratory tract infections 
[1–4].
Cefuroxime axetil contains three chiral centers and 
occurs in crystalline and amorphous forms. The stereo-
chemical properties of CA are essential for its bactericidal 
activity and affinity to biological membranes, while appear-
ance of its polymorphs is important during technological 
process of obtaining pharmaceutical dosage forms [5, 6].
Cefuroxime axetil is a mixture of two diastereoisomers 
(A and B). These diastereoisomers can be impurities as well 
as degradation products of parent drug. The Abbreviated 
New Drug Application (ANDA) has approved CA as an 
amorphous dispersion or an amorphous/crystalline mixture 
following the expiry of patent protection and the appear-
ance of generic products. It is suggested that the crystal-
line content in the mixture of cefuroxime axetil may “seed” 
crystallization of the amorphous form and so increases the 
content of the crystalline form that shows poorer solubility 
and bioavailability [7].
Chromatographic methods are the most commonly used for 
the determination of CA and its diastereoisomers in aqueous 
Abstract A sensitive UHPLC-DAD method was devel-
oped for determination of diastereoisomers of cefurox-
ime axetil in bulk substance in amorphous and crystalline 
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matographic separation was achieved on Kinetex C-18 
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the solid state were identified with a EIS-Q-MS mass spec-
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chromatographic separation of its diastereoisomers.
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solutions as well as in the solid state. The proposed conditions 
of chromatographic separation are based on the employment 
of ion pairs (e.g., phosphoric acid and its salts) and high con-
tent of organic modifier in the mobile phase [6, 8–11].
While the structure of related products of CA has been 
already described, studies focusing on the development of 
modern, fast and precise methods of its chromatographic 
separation, with potential of their application in drug qual-
ity control, should be carried out. Different solubility of 
cefuroxime axetil polymorphs should be taken into account 
in the preparation of the samples for chromatographic stud-
ies. Changes of solubility of samples under applied chro-
matographic conditions should be also excluded.
The aim of our studies was to develop fast and eco-
friendly UHPLC-DAD method allowing the determination 
of diastereoisomers of cefuroxime axetil in bulk substance 
as well as in pharmaceutical dosage forms. To achieve 
these objectives, preparation procedures of amorphous and 
crystalline CA were implemented.
Experimental
Materials
Cefuroxime axetil (amorphous and crystalline forms) was 
obtained from Institute of Biotechnology and Antibiotics 
in Warsaw, Poland. Zinnat® coated tablets were manufac-
tured by GlaxoSmithKline (Brentford, Middlesex, Great 
Britain). Zinoxx® coated tablets were produced by Pol-
farmex S.A. (Kutno, Poland). Xorimax® coated tablets 
were originally formulated by Sandoz (Kundl, Austria). 
All above-mentioned pharmaceutical preparations con-
tained 250 mg of cefuroxime axetil. Other chemicals and 
reagents were obtained from Merck KGaA (Darmstadt, 
Germany) and were of chromatographic grade. High-qual-
ity pure water was prepared using the Millipore purifica-
tion system (Millipore, Molsheim, France, model Exil SA 
67120).
Chromatographic Conditions
Chromatographic studies were performed on a Thermo 
Scientific UHPLC-UltiMate 3000 system. Diastereoiso-
mers of CA were separated with a Kinetex C-18 (100 mm 
times 2.1 mm, 1.7 µm) column as a stationary phase and 
a mixture of 0.1 % formic acid:methanol (88:12, v/v), 
at the flow rate of 0.7 mL min−1 as the mobile phase. 
The wavelength of the DAD detector was set at 278 nm. 
Separation was carried out at 40 °C. The injected volume 
was 5 µL. The components of mobile phase and sample 
solutions were filtered through 0.2 μm nylon membranes. 
A triple-quadrupole mass spectrometer model 6410B 





















































Fig. 1  Degradation pathways of cefuroxime axetil in aqueous solutions (a) and in solid state (b)
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from Agilent Technologies, USA) coupled with chroma-
tograph Agilent 1200 was used for identification of deg-
radation products of cefuroxime axetil. The ESI source 
of the MS detector was operated in a negative ioniza-
tion mode. For nebulization, a nitrogen stream at 40 psi 
(275.8 kPa) was applied. A drying gas, also nitrogen, 
was delivered at a flow rate of 8 L min−1 at 300 °C. The 
electrospray needle voltage was 4,000 V. The acquisition 
was carried out in the scan mode, and the spectra were 
collected in the range of m/z 40–600. The MassHunter 
workstation software (Agilent Technologies, USA) was 
used for the instrument control, data acquisition and data 
analysis. The identification of degradation products of 
cefuroxime axetil based on application of an EIS-Q-MS 
mass spectrometer was possible using the mobile phase, 
which composed of 0.1 % formic acid and methanol 
(50:50, v/v).
Preparation of Stock Solutions
Cefuroxime axetil powder (4.0 mg) was accurately 
weighted and transferred to a 10.0 mL volumetric flask. 
Amorphous form of CA sample was dissolved in a mixture 
of acetonitrile:water (50:50, v/v), while crystalline form 
of CA was dissolved in pure methanol. In both cases, final 
concentration 0.400 mg mL−1 of solution was achieved. 
Stock solutions were stored in darkness at 4 °C and proved 
stable during the time of the study.
Preparation of Sample Solution
Assay of Cefuroxime Axetil in Bulk Substance
Solutions of cefuroxime axetil in amorphous and crystal-
line forms were prepared in the same way as stock solu-
tions. The final concentration was also 0.400 mg mL−1.
Assay of Cefuroxime Axetil in Tablets
The amount of accurately powdered tablets (Zin-
nat®, Zinoxx® and Xormiax®) containing 250 mg of 
cefuroxime axetil was transferred to 50 mL volumet-
ric flasks, dissolved with about 30 mL of mixture of 
acetonitrile:water (50:50, v/v), mixed in an ultrasound 
bath for 15 min, filled to volume with the same sol-
vent and filtered. 2.0 mL of so-obtained solutions 
was transferred to 25 mL volumetric flasks and filled 
to volume with mixture of acetonitrile:water (50:50, 
v/v). The final concentration 0.400 mg mL−1 was 
achieved. In addition, pharmaceutical dosage forms of 
CA (Zinnat®, Zinoxx® and Xormiax®) were also pre-
pared in analogous manner using pure methanol as a 
solvent.
Validation Methodology
The method was validated by evaluation of selectivity, lin-
earity range, precision, accuracy, limit of detection (LOD) 
and limit of quantification (LOQ). The validation was car-
ried out according to the International Conference of Har-
monization Guidelines [12].
Selectivity Studies
To evaluate the applicability of proposed UHPLC-DAD chro-
matographic method in determination of CA in bulk sub-
stance and in pharmaceutical dosage forms (Zinnat®, Zinoxx® 
and Xormiax® tablets), degradation studies in conditions of 
increased temperature and humidity were performed. 5 mg sam-
ples of CA in amorphous and crystalline forms were weighted 
into 5 mL glass vials and exposed to increase relative humidity 
(RH = 90 %) at 363 K for 12 h. Applied stress conditions simu-
lated possible changes in CA in the solid state during its storage. 
Zinnat®, Zinoxx® and Xormiax® tablets were stored in the same 
conditions without commercial packages. The identification of 
degradation products of CA was carried out in aqueous solu-
tions (0.5 mol L−1 NaOH at 298 K for 0.5 min) as well as in the 
solid state (RH = 76 % at 353 K for 6 days).
Linearity
To confirm the linearity, eleven standard solutions of CA 
for both polymorphic forms, in the concentration range 
40.0–480.0 μg mL−1 (10–120 % of the targeted level of the 
assay concentration for cefuroxime axetil), were prepared. 
Each sample was injected in triplicate to evaluate the repro-
ducibility of detector response at each concentration level. 
The linearity was also investigated for the assay of CA in 
Zinnat®, Zinoxx® and Xormiax® tablets. The same concen-
tration ranges were applied.
Precision
Precision of the chromatographic method was determined 
for three concentrations of cefuroxime axetil (in bulk sub-
stance and in tablets): 320.0, 400.0 and 480.0 μg mL−1. 
Each of above-mentioned solutions was injected six times 
during the same day to evaluate repeatability (intra-day 
precision) of proposed analytical procedure.
Accuracy
To confirm the accuracy of the UHPLC-DAD method, 
recovery test was performed at three concentration levels: 
320.0, 400.0 and 480.0 μg mL−1. Known amounts of the 
reference substance were added at the beginning of the pro-
cess. Each sample was injected six times.
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Limits of Detection (LOD) and Quantification (LOQ)
The LOD and LOQ were calculated from the regres-
sion equation of the cefuroxime axetil: LOD = 3.3 (Sy/a), 
LOQ = 10 (Sy/a), where Sy is a standard error and a is the 
slope of the corresponding calibration curve.
Results and Discussion
The separation of diastereoisomers A and B of cefuroxime 
axetil in amorphous and crystalline polymorphic forms was 
possible as the result of application of C-18 1.7 μm col-
umn as a stationary phase. As the mobile phase, a mixture 
of 0.1 % formic acid and methanol (88:12, v/v) with flow 
rate 0.7 mL min−1 was used. To evaluate the robustness 
of proposed chromatographic procedure, the influence of 
changes of the following parameters on the peak properties 
was investigated: the composition of mobile phase (con-
centration of methanol in the range 86–90 %), flow rate 
(in the range 0.6–0.8 mL min−1), absorption wavelength 
(278 ± 5 nm), and column temperature (40 ± 5 °C). It 
was observed that column temperature and flow rate of the 
mobile phase play a crucial role in the separation of dias-
tereoisomers of CA. The most satisfactory resolution was 
reached when the column temperature was set at 40 °C, 
with the flow rate 0.7 mL min−1.
Proposed chromatographic method represents better 
separation parameters than pharmacopoeial assay. Recom-
mended values such as relative retention of diastereoisomer 
Fig. 2  UHPLC chromatograms of non-degraded and degraded samples of CA in bulk substance (amorphous form: a and b, crystalline form: c 
and d) and in tablets (e and f) (A and B—diastereoisomers of CA; C and D—degradation products)
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B in comparison to the diastereoisomer A, ratio of diaste-
reoisomers and run time of analysis are 1.20, 0.48–0.55 
and 25 min for pharmacopoeial method, respectively [10, 
13]. While in our studies, we obtained the following val-
ues of these parameters: 0.90, 0.75–0.81 and 3 min, respec-
tively. The above-mentioned values of parameters based on 
UHPLC procedure were established for determination of 
CA in bulk substance as well as in pharmaceutical prepara-
tions (Zinnat®, Zinoxx® and Xormiax® tablets).
In comparison to HPLC procedures which have been 
previously reported for determination of cefuroxime axetil 
in the presence of its degradation products, the proposed 
UHPLC-DAD method represents better parameters of 
chromatographic separation, which is connected with the 
specification of UHPLC procedure. Its application also pro-
vides achievement of more satisfying validation parameters 
[6, 8, 11].
The selectivity of the method for determination of dias-
tereoisomers A and B of cefuroxime axetil in amorphous 
and crystalline forms was confirmed after dissolution of 
the samples in the mixture of acetonitrile:water (50:50, 
v/v) or in pure methanol. The solubility of amorphous 
and crystalline forms of CA was found to be the highest 
in above-mentioned suitable solvents. For amorphous form 
of CA, the most satisfactory parameters of the peaks were 
observed when the sample was dissolved in the mixture of 
acetonitrile:water (50:50, v/v) [10]. However, in the case of 
crystalline form, the best resolution and asymmetry were 
achieved using pure methanol. Under applied chromato-
graphic conditions, diastereoisomers of cefuroxime axetil 
in bulk substance were well separated and retention times 
were: from about 0.35–0.40 min for diastereoisomer A and 
from 0.40 to 0.45 min for diastereoisomer B (Fig. 2a, b). 
On chromatograms of degraded samples of cefuroxime 
axetil, peaks originating from degradation products were 
observed at retention times from about 0.72 to 1.25 min 
(Fig. 2c, d). The degradants were not interfering with the 
main peaks.
To exclude the impact of excipients present in Zin-
nat®, Zinoxx® and Xormiax® and to evaluate the specific-
ity of developed chromatographic method in determina-
tion of diastereoisomers A and B, CA selectivity studies 
for non-degraded and degraded tablets were carried out. 
The same procedure as in the case of bulk substance was 
applied. It was observed that after dissolution of tablets 
containing CA in pure methanol, unsatisfied results were 
obtained. This may be because the content of the crystalline 
form of cefuroxime axetil in investigated pharmaceutical 
preparations is insignificant, and therefore the mixture of 
acetonitrile:water (50:50, v/v) is a better solvent.
Peaks derived from diastereoisomers of CA in non-
degraded tablets represented satisfactory separation and 
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while retention time of diastereoisomer B was about 
0.45 min. The parameters of peaks were equal in all studied 
pharmaceutical formulations (Fig. 2e). In chromatograms 
obtained from forced degraded tablets, samples peaks 
originated from degradation products appeared at about 
0.68 min and 0.88 min (Fig. 2f). Similarly, in the case of 
CA in bulk substance, degradants were not interfering with 
the main peaks.
As expected, the studies of degradation pathways in 
aqueous solution showed that CA under applied conditions 
(0.5 mol L−1 NaOH at 298 K for 0.5 min) was hydrolysed 
into its acidic form—cefuroxime. Both diastereoisomers 
were degraded with similar rate (Fig. 1a). However, in the 
solid state (RH = 76 % at 353 K for 6 days), the decom-
position of CA proceeded multidirectionally, including 
changes in azabicyclic structure and substituents which can 
be connected with various degradation rates of diastereoi-
somers A and B (Fig. 1b).
Spectroscopic purity of peaks of CA in non-degraded 
and degraded samples (in bulk substance and in tablets) 
remained unchanged during the stability studies (>98 % 
purity of the peak) and was sufficient to confirm the selec-
tivity of proposed analytical method. The calibration plots 
for diastereoisomers A and B of CA, in bulk substance 
and in Zinnat®, Zinoxx®, Xormiax® tablets, concentra-
tion range in which the method represents the linearity and 
standard deviation values are summarized in Table 1.
Precision of the proposed method was characterized by 
relative standard deviation (RSD, %) which was calculated 
for six consecutive measurements at three concentration lev-
els: 80 % (c = 320 μg mL−1), 100 % (c = 400 μg mL−1) 
and 120 % (c = 480 μg mL−1) of standard solutions during 
the system suitability test. Under developed chromatographic 
conditions, the investigation of precision was conducted in 
regards to content of diastereoisomers A and B of cefuro-
xime axetil in bulk substance in amorphous and crystalline 
forms and in pharmaceutical preparations (Zinnat®, Zinoxx® 
and Xormiax®). The values characterizing inter-day preci-
sion are collected in Table 2. All values which characterize 
the inter-day precision of determination of diastereoisomers 
of cefuroxime axetil were less than 2 % and meet the criteria 
required for the precision of the method.
The accuracy of the developed UHPLC-DAD method was 
evaluated by analyzing contents of diastereoisomers A and B 
in amorphous and crystalline forms of CA in bulk substance 
and in pharmaceutical preparations. The average values of 
the recoveries and standard deviations showed that applied 
extraction procedure is satisfied and reproducible (Table 2).
LOD and LOQ values were calculated for determination 
of diastereoisomers A and B of cefuroxime axetil in bulk 
substance (in both polymorphic forms) and in tablets are 
shown in Table 1.
Conclusions
The developed UHPLC-DAD method allows the determi-
nation of diastereoisomers A and B of cefuroxime axetil in 
the presence of its degradation products, in bulk substance 
(in amorphous and crystalline forms) and in pharmaceuti-
cal preparations. The main degradation pathways of CA in 
aqueous solutions led towards its acidic form and the degra-
dation rates of diastereoisomers A and B were similar. The 
degradation of CA in the solid state was multidirectional 
which can be connected with differences in decomposition 
rates of its diastereoisomers. Thanks to the employment 
of UHPLC procedure the content of organic modifier was 
significantly limited (from 38 to 12 %), short run time of 
analysis (about eight times shorter than in the case of phar-
macopoeial method) and satisfactory validation parameters 
were achieved, what meets the requirements of modern and 
eco-friendly analytical approaches. Attention, however, 
Table 2  Inter-day precision and recovery of diastereoisomers of cefuroxime axetil in bulk substance and in tablets
A diastereoisomer A of cefuroxime axetil, B diastereoisomer B of cefuroxime axetil
Spiked concentration (μg mL−1) Bulk substance Tablets
Amorphous form Crystalline form Zinnat® Zinoxx® Xorimax®
A B A B A B A B A B
Inter-day precision (RSD, %)
 320 2.13 1.12 2.53 2.83 0.67 0.78 0.60 0.78 0.83 0.51
 400 1.54 1.82 1.07 0.63 0.39 1.66 0.68 1.66 0.54 0.88
 480 1.64 1.15 2.83 1.88 0.74 0.85 0.77 0.85 0.31 1.30
Recovery (RSD, %)
 320 98.95 98.48 99.99 104.99 99.62 99.66 99.57 100.19 99.64 99.86
 400 98.31 99.92 99.40 99.65 100.20 100.40 100.36 100.49 99.78 99.58
 480 99.52 99.89 100.02 99.99 100.60 100.41 99.66 99.24 100.02 99.58
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focuses on the necessity of using suitable procedure for the 
preparation of samples containing different polymorphic 
forms of cefuroxime axetil.
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